Neuropace Inc SEC Filings

NeuroPace Inc director and CEO Joel Becker had 1,126 shares of Common Stock withheld on May 27, 2026 to cover taxes from a restricted stock unit vesting. This was a tax-withholding disposition by the company rather than an open-market sale.

Following the withholding, Becker directly holds 141,691 shares of NeuroPace Common Stock. The transaction reflects routine tax treatment of equity compensation and does not represent a discretionary buy or sell decision in the market.

NeuroPace Inc chief medical officer Martha Morrell reported a routine tax-withholding transaction related to equity compensation. On May 27, 2026, 358 shares of common stock were withheld by the company to cover tax obligations triggered by the vesting of a restricted stock unit award. This was not an open-market sale. After this withholding, she directly held 52,385 shares of NeuroPace common stock.

NeuroPace Inc Chief Financial Officer Patrick F. Williams reported equity compensation awards consisting of restricted stock units and stock options. He received 16,820 shares of Common Stock as a grant, taking his directly held Common Stock to 68,670 shares after the award.

The grant is in the form of RSUs, each representing one share of common stock upon settlement, with 25% vesting on May 15, 2027 and the remainder vesting in 12 equal quarterly installments thereafter. He was also granted stock options for 44,800 shares at an exercise price of $15.36 per share, expiring on May 14, 2036, with 25% vesting on May 15, 2027 and the rest vesting in 36 equal monthly installments.

NeuroPace Inc reported that Chief Medical Officer Martha Morrell received new equity awards. She acquired 5,460 shares of common stock in the form of restricted stock units, bringing her direct holdings to 52,743 shares of common stock.

She was also granted a stock option for 14,550 shares of common stock at an exercise price of $15.36 per share, expiring on May 14, 2036. The RSUs and options each vest 25% on May 15, 2027, with the remaining portions vesting over subsequent quarterly and monthly installments, respectively.

NeuroPace Inc CEO Joel Becker reported equity awards consisting of restricted stock units and stock options. He received 45,880 RSU-based shares of common stock, bringing his common stock holdings to 142,817 shares. He was also granted options on 122,190 shares at an exercise price of $15.36, expiring on May 14, 2036.

The RSUs vest 25% on May 15, 2027, with the remainder in twelve equal quarterly installments. The stock options vest 25% on May 15, 2027, with the remaining shares vesting in thirty-six equal monthly installments thereafter.

NeuroPace, Inc. filed a Schedule 13G reporting joint beneficial ownership by First Light Asset Management, LLC and Mathew P. Arens as to shares of Common Stock.

The filing states First Light holds 2,865,423 shares (8.40%) and Mr. Arens holds 2,955,423 shares (8.67%), with the holdings reported in Item 4 and dated 03/31/2026. The Manager exercises shared voting and dispositive power over 2,865,423 shares, while Mr. Arens reports 60,000 shares of sole voting and dispositive power.

NeuroPace Inc ownership update: OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC each report beneficial ownership of 2,096,527 shares of Common Stock, representing 6.2% of the class. The filings state the shares are held in aggregate on behalf of others and that shared voting and dispositive power over these shares is exercised by the reporting persons through a management committee.

NeuroPace, Inc. reported first‑quarter 2026 revenue of $22.1 million, slightly below the prior year as DIXI distribution revenue rolled off but RNS System unit volumes increased. Gross margin improved to 81.8% as higher‑margin RNS sales replaced lower‑margin distributed products.

The company posted a net loss of $6.7 million, or $0.20 per share, similar to the prior‑year loss. Cash, cash equivalents and short‑term investments totaled $54.0 million, with $59.0 million of term debt outstanding under its MidCap facility, and management believes liquidity supports at least 12 months of operations while remaining in covenant compliance.

NeuroPace is exiting its DIXI Medical distribution agreement, expects to treat it as discontinued operations once remaining inventory is returned, and continues to pursue label expansion for its RNS System, including idiopathic generalized and pediatric focal epilepsy indications, alongside ongoing investments in R&D and commercial expansion.

NeuroPace, Inc. reported strong first quarter 2026 growth and raised its full-year revenue outlook. Non-GAAP revenue (excluding DIXI Medical) rose 20.1% to $22.0 million from $18.3 million a year earlier, driven by RNS System revenue of $21.7 million, up 19.5%.

Non-GAAP gross margin was 82.5%, while GAAP net loss was ($6.7) million. On a non-GAAP basis, loss from operations improved to ($3.3) million from ($4.1) million, and non-GAAP net loss narrowed to ($4.4) million from ($5.6) million.

For full year 2026, NeuroPace now expects revenue between $99 million and $101 million, implying 21%–23% underlying RNS growth, and reiterates non-GAAP gross margin of 81.5%–82.5% and non-GAAP operating expenses of $90–$92 million. Adjusted EBITDA is guided to a loss of ($8.5)–($9.5) million. The company completed the FDA mid-cycle review for its NAUTILUS PMA supplement and plans to report DIXI Medical as discontinued operations starting in the second quarter.